Old Web
English
Sign In
Acemap
>
authorDetail
>
Xuejun V. Peng
Xuejun V. Peng
Takeda Pharmaceutical Company
Endocrinology
Internal medicine
Diabetes mellitus
Glycemic
Biology
4
Papers
6
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
965-P: Real-World Evidence of the Effect on Glycemic Control with Relatively Simultaneous vs. Sequential Initiation of Basal Insulin and GLP-1 Receptor Agonists
2020
Diabetes
Julio Rosenstock
Francisco Javier Ampudia-Blasco
Robert Lubwama
Xuejun V. Peng
Anders Hasager Boss
Lizheng Shi
Vivian Fonseca
Show All
Source
Cite
Save
Citations (0)
345-OR: A Retrospective U.S. Real-World Evidence Study on Glycemic Goal Achievement within 2 Years Post-Basal Insulin Initiation
2019
Diabetes
Xuejun V. Peng
Phillip R. Hunt
Terry Dex
Robert Lubwama
Neil Skolnik
Lawrence Blonde
Show All
Source
Cite
Save
Citations (0)
1116-P: Glycemic Outcomes and Persistence with Basal Insulin and Glucagon-Like Peptide-1 Receptor Agonists among Patients with T2D: Simultaneous vs. Sequential Initiation
2019
Diabetes
Xuejun V. Peng
Rajeev Ayyagari
Robert Lubwama
Melvin J. Van Vleet
Lizheng Shi
Eboni G. Price-Haywood
Priscilla Hollander
Vivian Fonseca
Show All
Source
Cite
Save
Citations (0)
Combining the G‐protein‐coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12‐week trial
2017
Diabetes, Obesity and Metabolism
Xuejun V. Peng
John Marcinak
Marsha Raanan
Charlie Cao
Show All
Source
Cite
Save
Citations (6)
1